the compound of formula i is a putative antipsychotic compound with affinity for both dopamine d1 and d2 receptors . preclinical experiments in rats using the condition avoidance response ( car ) model ( experimental procedure previously described in : hertel p , olsen c k , arnt j . repeated administration of the neurotensin analogue nt69l induces tolerance to its suppressant effect on conditioned avoidance behaviour . eur j pharmacol . 2002 ; 439 ( 1 - 3 ): 107 - 11 .) have indicated that the compound of formula i possesses antipsychotic activity at very low levels of d2 receptor occupancy . in a positron emission tomography ( pet ) study in healthy subjects using 11c - sch23390 and 11 c - raclopride as d1 and d2 receptor tracers , it was found that the compound of formula i induces a d2 receptor occupancy of from 11 to 43 % in the putamen when increasing the dose from 2 to 10 mg / day given daily for 18 days . such level of d2 receptor occupancy is low in comparison with that of currently used antipsychotic drugs , which in general requires a d2 receptor occupancy around or exceeding 50 % to be therapeutically effective ( stone j m , davis j m , leucht s , pilowsky l s . cortical dopamine d2 / d3 receptors are a common site of action for antipsychotic drugs ; an original patient data meta - analysis of the spect and pet in vivo , schizophr bull . 2008 feb . 26 . [ epub in advance of print ].). in the same pet study , it was found that the compound of formula i induces a d1 receptor occupancy increase from 32 to 69 % in putamen when increasing the dose from 2 to 10 mg / day given daily for 18 days . such high level of d1 occupancy is not generally seen with current used antipsychotic drugs ( farde l , nordstrom a l , wiesel f a , pauli s , halldin c , sedvall g . positron emission tomographic analysis of central d1 and d2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine . relation to extrapyramidal side effects . arch gen psychiatry . 1992 ; 49 ( 7 ): 538 - 44 .). thus , the compound of formula i exhibits a unique ratio of d1 to d2 receptor occupancy at low daily doses . based on the above , it is expected that the compound of formula i have clinically significant therapeutic effects in patients with schizophrenia at doses ( from 4 mg / day to 14 mg / day ) that induce only a low level of d2 receptor occupancy . this might well be a consequence of the high d1 receptor occupancy and the unique ratio of d1 versus d2 receptor occupancy displayed by the compound of formula i . a low d2 receptor occupancy at therapeutically effective doses will be beneficial in terms of reduced tendency to induce troublesome side effects mediated by d2 receptor blockade , including extrapyramidal side effects and hyperprolactinemia . the compound of formula i in a therapeutically effective amount of from 4 - 14 mg calculated as the free base is administered orally , and may be presented in any form suitable for such administration , e . g . in the form of tablets , capsules , powders , syrups or solutions . in one embodiment , a salt of the compound of formula i is administered in the form of a solid pharmaceutical entity , suitably as a tablet or a capsule . methods for the preparation of solid pharmaceutical compositions or preparations are well known in the art . thus , tablets may be prepared by mixing the active ingredient with conventional adjuvants , fillers and diluents and subsequently compressing the mixture in a suitable tabletting machine . examples of adjuvants , fillers and diluents comprise cornstarch , lactose , talcum , magnesium stearate , gelatine , gums , and the like . typical fillers are selected from lactose , mannitol , sorbitol , cellulose and microcrystalline cellulose . any other adjuvant or additive such as colourings , aroma , preservatives , etc , may also be used provided that they are compatible with the active ingredient . as used throughout the present description the term “ compound of formula i ” is intended to designate any form of the compound , such as the free base , pharmaceutically acceptable salts thereof , eg . pharmaceutically acceptable acid addition salts , such as succinate and malonate salts , hydrates or solvates of the free base or salts thereof , as well as anhydrous forms , amorphous forms , or crystalline forms . the compound of formula i to be comprised in the composition of the present invention also comprises salts thereof , typically , pharmaceutically acceptable salts . such salts include pharmaceutical acceptable acid addition salts . acid addition salts include salts of inorganic acids as well as organic acids . representative examples of suitable inorganic acids include hydrochloric , hydrobromic , hydroiodic , phosphoric , sulfuric , sulfamic , nitric acids and the like . representative examples of suitable organic acids include formic , acetic , trichloroacetic , trifluoroacetic , propionic , benzoic , cinnamic , citric , fumaric , glycolic , itaconic , lactic , methanesulfonic , maleic , malic , malonic , mandelic , oxalic , picric , pyruvic , salicylic , succinic , methane sulfonic , ethanesulfonic , tartaric , ascorbic , pamoic , bismethylene salicylic , ethanedisulfonic , gluconic , citraconic , aspartic , stearic , palmitic , edta , glycolic , p - aminobenzoic , glutamic , benzenesulfonic , p - toluenesulfonic acids , theophylline acetic acids , as well as the 8 - halotheophyllines , for example 8 - bromotheophylline and the like . further , the compound of formula i may exist in unsolvated form , as well as in solvated forms with pharmaceutically acceptable solvents such as water , ethanol and the like . in general , solvated forms are considered to be equivalent to unsolvated forms for the purposes of this invention . the present invention relates to a pharmaceutical composition comprising the compound of formula ( i ) in a therapeutically effective amount of from 4 - 14 mg calculated as the free base . in a further embodiment , the composition comprising the compound of formula i is for treatment of cognitive dysfunction , schizophrenia , schizophreniform disorder , schizoaffective disorder , delusional disorder , brief psychotic disorder , shared psychotic disorder , mania in bipolar disorder , anxiety disorders , depression , maintenance of bipolar disorders , sleep disturbances , migraine , neuroleptic - induced parkinsonism , or cocaine abuse , nicotine abuse , or alcohol abuse . typical use of the composition of the invention is in the treatment of schizophrenia , such as positive symptoms of schizophrenia , or cognitive dysfunction in schizophrenia . in a further aspect the present invention relates to use of a compound of formula ( i ) for the preparation of a medicament for treatment of cognitive dysfunction , schizophrenia , schizophreniform disorder , schizoaffective disorder , delusional disorder , brief psychotic disorder , shared psychotic disorder , mania in bipolar disorder , anxiety disorders , depression , maintenance of bipolar disorders , sleep disturbances , migraine , neuroleptic - induced parkinsonism , or cocaine abuse , nicotine abuse , or alcohol abuse , wherein the compound of formula i is present in a therapeutically effective amount of from 4 - 14 mg calculated as the free base . in a further aspect the present invention also relates to a method of treating cognitive dysfunction , schizophrenia , schizophreniform disorder , schizoaffective disorder , delusional disorder , brief psychotic disorder , shared psychotic disorder , mania in bipolar disorder , anxiety disorders , depression , maintenance of bipolar disorders , sleep disturbances , migraine , neuroleptic - induced parkinsonism , or cocaine abuse , nicotine abuse , or alcohol abuse , comprising administering a therapeutically effective amount of from 4 - 14 mg calculated as the free base of the compound of formula ito a patient in need thereof . in an embodiment of the composition , the use , or the method of treatment of the invention , the compound of formula i is formulated for oral administration , such as a tablet or capsule , typically a tablet . the composition , such as a tablet , is typically for oral administration once daily . in a further embodiment of the composition , the use , or the method of treatment , the compound of formula i is in the form of a succinate or malonate salt . typically , the succinate salt . in further embodiments of the composition , use , or method of treatment , the amount of the compound of formula ( i ) is from 4 - 12 mg . in further embodiments of the composition , use , or method of treatment , the amount of the compound of formula ( i ) is from 5 - 14 mg . in further embodiments of the composition , use , or method of treatment , the amount of the compound of formula ( i ) is from 4 - 6 mg , such as 5 mg . in further embodiments of the composition , use , or method of treatment , the amount of the compound of formula ( i ) is from 6 - 8 mg , such as 7 mg . in further embodiments of the composition , use , or method of treatment , the amount of the compound of formula ( i ) is from 8 - 10 mg . in further embodiments of the composition , use , or method of treatment , the amount of the compound of formula ( i ) is from 10 - 12 mg . in further embodiments of the composition , use , or method of treatment , the amount of the compound of formula ( i ) is from 12 - 14 mg , such as 14 mg . in further embodiments of the composition , use , or method of treatment , the amount of the compound of formula ( i ) is from 5 - 7 mg . in further embodiments of the composition , use , or method of treatment , the amount of the compound of formula ( i ) is from 7 - 9 mg . in further embodiments of the composition , use , or method of treatment , the amount of the compound of formula ( i ) is from 9 - 11 mg , such as 10 mg in further embodiments of the composition , use , or method of treatment , the amount of the compound of formula ( i ) is from 11 - 13 mg . when the invention relates to the use or the method of treatment then the dose indicated above of from 4 - 14 mg , such as 5 mg , 7 mg , 10 mg , or 14 mg , is on a daily basis . in a further embodiment of the composition , the use , or the method of treatment , the composition further comprises povidone , such as kollidone 30 ( cas - no . 94800 - 10 - 9 ), or copovidone , such as kollidone va64 ( cas - no . 25086 - 89 - 9 ), as a binder . the binder is typically present in a concentration range of from 2 - 10 % ( w / w ), such as 2 - 4 %, 4 - 6 %, 6 - 8 %, 8 - 10 %, 2 - 8 %, 4 - 8 %, 4 - 10 %, or 6 - 10 % ( w / w ). in a further aspect the present invention also relates to a pharmaceutical composition comprising the compound of formula ( i ) and povidone or copovidone as binder . typically the binder is kollidone va64 . in an embodiment the binder is present in a concentration range of from 2 - 10 % ( w / w ). typically in a concentration range of from 2 - 4 %, 4 - 6 %, 6 - 8 %, or 8 - 10 % ( w / w ). when the binder is povidone or copovidone typical fillers are selected from calcium hydrogen phosphate lactose , mannitol , sorbitol , cellulose and microcrystalline cellulose , and preferably lactose , mannitol , sorbitol , cellulose and microcrystalline cellulose , such as lactose . in an embodiment the filler , such as anyone of the above , is in a concentration range of from 15 - 50 % ( w / w ). typically , the filler , such as anyone of lactose , mannitol , sorbitol , cellulose and microcrystalline cellulose , is in a concentration range of from 15 - 25 %, 20 - 50 %, 30 - 45 % ( w / w ). in a further embodiment of the composition the compound of formula ( i ) is in the form of the succinate salt . the safety and efficacy of the compound of formula i in schizophrenic patient will be investigated by standard measures of efficacy ( including the positive and negative syndrome scale [ panss ] and the clinical global impressions scale [ cgi ]) and safety . after a screening period , eligible patients will be randomised in a 2 : 1 ratio to blinded treatment with either the compound of formula i ( e . g . at doses of 5 , 7 , 10 and 14 mg / day ) or placebo for 8 weeks . the study includes 5 parts with increasing doses of the compound of formula i and a decision to initiate the next dose level will be based on safety and tolerability assessment based on the previous part of the study . the efficacy and the safety of the compound of formula i will be evaluated in comparison to the pooled placebo group from all parts of the study . the compound of formula i has been shown to possess cognition enhancing properties in preclinical models of cognitive dysfunctions . it is believed that the 5 - ht6 receptor affinity of the compound of formula i is involved in the precognitive effects of the compound . furthermore , it is believed that such pro - cognitive effect of the compound of formula i will be evident at a low level of d2 receptor occupancy , which is beneficial in terms of the side - effect profile . the effect of the compound of formula i on cognitive deficits in schizophrenic patients will be assessed in a clinical trial where eligible patients will be randomised in a 1 : 1 ratio to blinded treatment with flexible doses of either the compound of formula i ( 5 to 7 mg / day ) or olanzapine ( 10 to 15 mg / day ) for 12 weeks . the efficacy of the compound of formula i on cognitive symptoms will be assessed using the brief assessment of cognition in schizophrenia ( bacs ) scale ( keefe r s , goldberg t e , harvey p d , gold j m , poe m p , coughenour l . the brief assessment of cognition in schizophrenia : reliability , sensitivity , and comparison with a standard neurocognitive battery . schizophr res . 2004 ; 68 ( 2 - 3 ): 283 - 97 . i . schizophr res . 2004 ; 68 ( 2 - 3 ): 283 - 97 .). preparation of immediate release film - coated tablet intended for oral administration i a study of the compatibility of the excipients and compound of formula i demonstrated that the components used in the tablet formulation were compatible with the compound . based on this , a traditional wet granulation , tabletting and film - coating process was developed using standard methods and excipients . the compound of formula i is formulated as immediate release film - coated tablet intended for oral administration . tablets containing compound of formula i in this example are made in two strengths , 5 and 7 mg . the product containing compound of formula i is a white film - coated tablet encapsulated in a brownish red hard capsule . other strengths , such as 4 , 6 , 8 , 9 , 10 , 11 , 12 , 13 , or 14 mg , may be prepared in the same manner . the compositions of the tablets 5 mg and 7 mg are given below in table 1 . the method of granulation is a traditional wet granulation process using copovidone ( kollidone va64 ) as a dry binder and water as granulation liquid . in the 10 - litre pma1 high shear mixer the process is as follows for a 2 kg batch : mix compound of formula i succinate , anhydrous calcium hydrogen phosphate , maize starch and copovidone for 2 minutes at 500 rpm . granulate at 800 rpm for approximately 4 minutes , so a suitable granule size is achieved . dry the granules in a tray dryer at 50 ° c ., until the product has a relative humidity ( rh ) of 25 - 55 % rh . mix the granules with microcrystalline cellulose , croscarmellose sodium and talc in a mixer . film - coat the tablet cores in a film coater , using the process parameters given in table 3 . in order to optimise the agglomeration process , two different tablet formulations was produced and their effect on the chemical stability of compound of formula i was evaluated . the composition of these tablets are given in table 4 , and the manufacturing process , was similar to the one described above : the use of copovidone as binder leads to tablets with better pharmaceutical technical properties , e . g . the cabability of producing harder tablets with low loss on friability without compromising the disintegration time , as demonstrated in table 5 : a study of the compatibility of the excipients and compound i demonstrated that the components used in the tablet formulation were compatible with the compound . based on this , a traditional wet granulation , tabletting and film - coating process was developed using standard methods and excipients . compound i is formulated as immediate release film - coated tablet intended for oral administration . tablets containing compound of formula i in this example are made in two strengths , 2 . 5 and 5 mg . the product containing compound of formula i is a white film - coated tablet encapsulated in a brownish red hard capsule . other strengths , such as 2 , 3 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , or 14 mg , may be prepared in the same manner . the compositions of the tablets 2 . 5 mg and 5 mg are given below in table 7 . in order to optimise the agglomeration process , one tablet formulation ( 2 . 5 mg ) for each binder was produced and the effect of binder on the chemical stability of compound i was evaluated . the composition of these tablets is given in table 9 , and the manufacturing process , was similar to the one described above . the use of copovidone as binder ( formulation no . 6 ) leads to tablets with good pharmaceutical technical properties , e . g . a relative long disintegration time permitting the tablets to be swallowed as whole tablets ( as demonstrated in table 10 ) and acceptable stability data ( as demonstrated in table 11 ): a study of the compatibility of the excipients and compound i demonstrated that the components used in the tablet formulation were compatible with the compound . based on this , a traditional wet granulation , tabletting and film - coating process was developed using standard methods and excipients . compound i is formulated as immediate release film - coated tablet intended for oral administration . tablets containing compound of formula i in this example are made in two strengths , 2 . 5 and 5 mg . the product containing compound of formula i is a white film - coated tablet encapsulated in a brownish red hard capsule . other strengths , such as 2 , 3 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , or 14 mg , may be prepared in the same manner . the compositions of the tablets 2 . 5 mg and 5 mg are given below in table 12 and table 13 . manufacturing process and process controls is as in example 1 . a flow diagram of the manufacturing process and process controls is shown in fig1 .
the invention relates to a pharmaceutical composition intended for oral administration comprising low doses of 4 -- 6 - chloro - 3 - phenylindan - 1 - yl )- 1 , 2 , 2 - trimethylpiperazine and to a composition comprising the compound .